Sharma B, Agriantonis G, Shafaee Z, Twelker K, Bhatia N, Kuschner Z
Cancers (Basel). 2024; 16(23).
PMID: 39682237
PMC: 11639870.
DOI: 10.3390/cancers16234051.
Yao M, Su Y, Xiong R, Zhang X, Zhu X, Chen Y
Sci Rep. 2024; 14(1):26724.
PMID: 39496747
PMC: 11535471.
DOI: 10.1038/s41598-024-77856-y.
Alom M, Jibon M, Faruqe M, Rahman M, Akter F, Ali A
Biomed Res Int. 2024; 2024:6810200.
PMID: 39184354
PMC: 11343637.
DOI: 10.1155/2024/6810200.
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L
Nat Commun. 2024; 15(1):6740.
PMID: 39112531
PMC: 11306361.
DOI: 10.1038/s41467-024-51214-y.
Liu Y, Yuan H, Fan J, Wang H, Xie H, Wan J
Discov Oncol. 2024; 15(1):266.
PMID: 38967893
PMC: 11226588.
DOI: 10.1007/s12672-024-01144-4.
Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming.
Akimoto T, Islam M, Nagasako A, Kishi K, Nakakaji R, Ohtake M
Cancer Sci. 2024; 115(8):2686-2700.
PMID: 38877783
PMC: 11309929.
DOI: 10.1111/cas.16243.
Prognostic value and drug sensitivity of F‑box and leucine‑rich repeat protein 6 in glioma.
Lin Q, Zhu J, Zhu W, Zhu H, Li M, Zhao J
Oncol Lett. 2024; 28(1):320.
PMID: 38807668
PMC: 11130608.
DOI: 10.3892/ol.2024.14453.
Polyphenols Modulate the miRNAs Expression that Involved in Glioblastoma.
Rezaie M, Nasehi M, Shimia M, Ebrahimnezhad M, Yousefi B, Majidinia M
Mini Rev Med Chem. 2024; 24(21):1953-1969.
PMID: 38639278
DOI: 10.2174/0113895575304605240408105201.
Glioblastoma modeling with 3D organoids: progress and challenges.
Wang X, Sun Y, Zhang D, Ming G, Song H
Oxf Open Neurosci. 2024; 2:kvad008.
PMID: 38596241
PMC: 10913843.
DOI: 10.1093/oons/kvad008.
Identification of PANoptosis-related predictors for prognosis and tumor microenvironment by multiomics analysis in glioma.
Sun F, Liao M, Tao Z, Hu R, Qin J, Tao W
J Cancer. 2024; 15(9):2486-2504.
PMID: 38577605
PMC: 10988298.
DOI: 10.7150/jca.94200.
vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.
Manzanares-Guzman A, Lugo-Fabres P, Camacho-Villegas T
Antibodies (Basel). 2024; 13(1).
PMID: 38534215
PMC: 10967338.
DOI: 10.3390/antib13010025.
Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A, Ardizzone A, Luca F, Colarossi L, Prestifilippo A, Pizzino G
Cells. 2024; 13(4.
PMID: 38391974
PMC: 10886920.
DOI: 10.3390/cells13040361.
A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs.
Wang C, Sun M, Shao C, Schlicker L, Zhuo Y, Harim Y
NPJ Precis Oncol. 2024; 8(1):19.
PMID: 38273014
PMC: 10811239.
DOI: 10.1038/s41698-024-00500-5.
Synthesis of alnustone-like diarylpentanoids via a 4 + 1 strategy and assessment of their potential anticancer activity.
Celebioglu N, Tozlu O, Turkez H, Secen H
Turk J Chem. 2024; 47(5):1249-1259.
PMID: 38173735
PMC: 10760875.
DOI: 10.55730/1300-0527.3609.
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.
Olatunji G, Aderinto N, Adefusi T, Kokori E, Akinmoju O, Yusuf I
Medicine (Baltimore). 2023; 102(48):e36421.
PMID: 38050252
PMC: 10695547.
DOI: 10.1097/MD.0000000000036421.
CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3.
Turchi L, Sakakini N, Saviane G, Polo B, Saurty-Seerunghen M, Gabut M
Cancers (Basel). 2023; 15(20).
PMID: 37894405
PMC: 10605641.
DOI: 10.3390/cancers15205038.
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B, Jenkins M, Best S, Freytag S, Prasad K, Holst J
Signal Transduct Target Ther. 2023; 8(1):400.
PMID: 37857607
PMC: 10587102.
DOI: 10.1038/s41392-023-01637-8.
Silencing GMPPB Inhibits the Proliferation and Invasion of GBM via Hippo/MMP3 Pathways.
Huang Z, Abdallah A, Shen G, Suarez M, Feng P, Yu Y
Int J Mol Sci. 2023; 24(19).
PMID: 37834154
PMC: 10572784.
DOI: 10.3390/ijms241914707.
Targeting Macrophages for Tumor Therapy.
Wang Y, Barrett A, Hu Q
AAPS J. 2023; 25(5):80.
PMID: 37589825
DOI: 10.1208/s12248-023-00845-y.
CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
Bhutada I, Khambati F, Cheng S, Tiek D, Duckett D, Lawrence H
Neuro Oncol. 2023; 26(1):70-84.
PMID: 37551745
PMC: 10768977.
DOI: 10.1093/neuonc/noad143.